Quanterix Corporation (QTRX)

NASDAQ: QTRX · Real-Time Price · USD
4.790
+0.030 (0.63%)
At close: Aug 13, 2025, 4:00 PM
4.700
-0.090 (-1.88%)
After-hours: Aug 13, 2025, 4:46 PM EDT
0.63%
Market Cap 222.80M
Revenue (ttm) 125.78M
Net Income (ttm) -70.50M
Shares Out 46.47M
EPS (ttm) -1.82
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 1,120,710
Open 4.770
Previous Close 4.760
Day's Range 4.560 - 5.040
52-Week Range 4.050 - 15.855
Beta 1.07
Analysts Hold
Price Target 11.75 (+145.05%)
Earnings Date Aug 7, 2025

About QTRX

Quanterix Corporation, a life sciences company, engages in development and marketing of digital immunoassay platforms that advances precision health for life sciences research and diagnostics in North America, Europe, the Middle East, Africa, and the Asia Pacific regions. The company offers HD-X instrument, a protein detection platform; and SR-X instrument that enables researchers to apply Simoa detection in an expanded range of applications. It also provides SP-X instrument that is based on Simoa planar array technology for the measurement of ... [Read more]

Industry Medical Devices
Sector Healthcare
IPO Date Dec 7, 2017
Employees 471
Stock Exchange NASDAQ
Ticker Symbol QTRX
Full Company Profile

Financial Performance

In 2024, Quanterix's revenue was $137.42 million, an increase of 12.30% compared to the previous year's $122.37 million. Losses were -$38.53 million, 35.9% more than in 2023.

Financial Statements

Analyst Forecast

According to 4 analysts, the average rating for QTRX stock is "Hold." The 12-month stock price target is $11.75, which is an increase of 145.05% from the latest price.

Price Target
$11.75
(145.05% upside)
Analyst Consensus: Hold
Stock Forecasts

News

Quanterix to Present at the Canaccord Genuity 45th Annual Growth Conference

BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultrasensitive biomarker detection, today announced that its executive leadershi...

2 days ago - Business Wire

Quanterix Corporation (QTRX) Q2 2025 Earnings Call Transcript

Quanterix Corporation (NASDAQ:QTRX) Q2 2025 Earnings Conference Call August 7, 2025 4:30 AM ET Company Participants Joshua Young - Corporate Participant Masoud Toloue - President, CEO & Director Vand...

4 days ago - Seeking Alpha

Quanterix Releases Financial Results for the Second Quarter of 2025

BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultra-sensitive biomarker detection, today announced financial results for the s...

6 days ago - Business Wire

Quanterix To Report Second Quarter 2025 Financial Results on August 7, 2025

BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultrasensitive biomarker detection, today announced that it will host a conferen...

9 days ago - Business Wire

Quanterix Announces Cooperation Agreement with Kent Lake Capital

BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (“Quanterix” or the “Company”) (NASDAQ: QTRX), a company fueling scientific discovery through ultrasensitive biomarker detection, today announc...

9 days ago - Business Wire

Quanterix Launches Novel p-Tau 205 and p-Tau 212 Assays to Advance Alzheimer's Research at AAIC

BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultrasensitive biomarker detection, today announced the first to market, commerc...

16 days ago - Business Wire

Quanterix Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (“Quanterix” or the “Company”) (NASDAQ: QTRX), a company fueling scientific discovery through ultra-sensitive biomarker detection, today announ...

4 weeks ago - Business Wire

Quanterix Completes Acquisition of Akoya Biosciences, Creating the First Integrated Platform Capable of Measuring Biomarkers Across the Blood and Tissue Continuum

BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (“Quanterix” or the “Company”) (NASDAQ: QTRX), a company fueling scientific discovery through ultra-sensitive biomarker detection, today announ...

5 weeks ago - Business Wire

Quanterix Expands Reach with IVD and Large Reference Labs

BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultrasensitive biomarker detection, today announced that the HD-X Simoa Immunoas...

7 weeks ago - Business Wire

Kent Lake Condemns Quanterix's Failure to Schedule Its 2025 Annual Meeting as a Tactic to Silence Shareholders

RINCON, Puerto Rico , June 11, 2025 /PRNewswire/ -- Kent Lake PR LLC ("Kent Lake"), a holder of approximately 6.9% of the outstanding common stock of Quanterix Corporation ("Quanterix" or the "Company...

2 months ago - PRNewsWire

Quanterix to Present at Goldman Sachs Global Healthcare Conference

BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultrasensitive biomarker detection, today announced that President and Chief Exe...

2 months ago - Business Wire

Kent Lake Responds to Quanterix's Post-Effective Amendment and Akoya's Superior $1.40-per-Share Alternative Proposal

RINCON, Puerto Rico , May 23, 2025 /PRNewswire/ -- Kent Lake PR LLC ("Kent Lake"), a holder of approximately 6.9% of the outstanding common stock of Quanterix Corporation ("Quanterix" or the "Company"...

Other symbols: AKYA
2 months ago - PRNewsWire

Quanterix Corporation (QTRX) Q1 2025 Earnings Call Transcript

Quanterix Corporation (NASDAQ:QTRX) Q1 2025 Earnings Conference Call May 12, 2025 4:30 PM ET Company Participants Joshua Young - Head, IR Masoud Toloue - President and CEO Vandana Sriram - CFO Confer...

3 months ago - Seeking Alpha

Quanterix Releases Financial Results for the First Quarter of 2025

BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultra-sensitive biomarker detection, today announced financial results for the f...

3 months ago - Business Wire

AKOYA BIOSCIENCES INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Akoya Biosciences, Inc. - AKYA

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Akoya Bioscience...

Other symbols: AKYA
3 months ago - Business Wire

Quanterix To Report First Quarter 2025 Financial Results on May 12, 2025

BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultrasensitive biomarker detection, today announced that it will host a conferen...

3 months ago - Business Wire

Kent Lake Issues Statement on Quanterix's Blatant Disregard for Will of Shareholders

RINCON, Puerto Rico--(BUSINESS WIRE)--Kent Lake PR LLC (“Kent Lake”), a holder of approximately 7.7% of the outstanding common stock of Quanterix Corporation (“Quanterix” or the “Company”) (NASDAQ: QT...

Other symbols: AKYA
3 months ago - Business Wire

Quanterix and Akoya Biosciences Announce Amended Merger Agreement

BILLERICA, Mass. & MARLBOROUGH, Mass.--(BUSINESS WIRE)--Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultra-sensitive biomarker detection, and Akoya Biosciences ...

Other symbols: AKYA
3 months ago - Business Wire

Kent Lake Files Definitive Proxy Statement and Sends Letter to Quanterix Shareholders

RINCON, Puerto Rico--(BUSINESS WIRE)--Kent Lake PR LLC (“Kent Lake”), a holder of approximately 7.7% of the outstanding common stock of Quanterix Corporation (“Quanterix” or the “Company”) (NASDAQ: QT...

4 months ago - Business Wire

Tikvah Management Calls on Quanterix to Explain the Egregious Terms of Convertible Notes Purchased from Akoya Biosciences

CHARLOTTE, N.C.--(BUSINESS WIRE)--Tikvah Management LLC (together with its affiliates, “Tikvah” or “we”), which owns approximately 1.5% of the outstanding common shares of Quanterix Corp. (“Quanterix”...

Other symbols: AKYA
4 months ago - Business Wire

Kent Lake Comments on Quanterix's Value Destructive Bridge Financing for Financially Troubled Akoya

RINCON, Puerto Rico--(BUSINESS WIRE)--Kent Lake PR LLC (“Kent Lake”) is a holder of approximately 7.5% of the outstanding common stock of Quanterix Corporation (“Quanterix” or the “Company”) (NASDAQ: ...

Other symbols: AKYA
4 months ago - Business Wire

Quanterix Showcases Innovation Powered by Simoa® at AD/PD with Customer Research and New Dried Blood Spot Extraction Kit

BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultrasensitive biomarker detection, today announced the inclusion of a new dried...

4 months ago - Business Wire

Tikvah Management Announces Intention to Vote AGAINST Quanterix's Proposed Merger with Akoya Biosciences

CHARLOTTE, N.C.--(BUSINESS WIRE)--Tikvah Management LLC (together with its affiliates, “Tikvah” or “we”), which owns approximately 1.5% of the outstanding common shares of Quanterix Corp. (Nasdaq: QTR...

Other symbols: AKYA
5 months ago - Business Wire

Quanterix Corporation (QTRX) Q4 2024 Earnings Call Transcript

Quanterix Corporation (NASDAQ:QTRX) Q4 2024 Earnings Conference Call March 17, 2025 4:30 PM ET Company Participants Joshua Young - Head of IR Masoud Toloue - President and CEO Vandana Sriram - CFO Co...

5 months ago - Seeking Alpha

Quanterix Releases Financial Results for the Fourth Quarter of 2024

BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultra-sensitive biomarker detection, today announced financial results for the f...

5 months ago - Business Wire